{"id":1930,"date":"2019-09-27T17:56:02","date_gmt":"2019-09-27T15:56:02","guid":{"rendered":"https:\/\/idibell.cat\/?page_id=1930"},"modified":"2024-12-13T13:49:02","modified_gmt":"2024-12-13T12:49:02","slug":"gynecologic-cancer-group","status":"publish","type":"page","link":"https:\/\/idibell.cat\/en\/research\/cancer-area\/molecular-mechanisms-and-experimental-therapy-in-oncology-program-oncobell\/gynecologic-cancer-group\/","title":{"rendered":"Gynecologic Cancer Group"},"content":{"rendered":"\n

\n\t\tGynaecological cancer group\n\t<\/h1>\n

\n\t\tSummary\n\t<\/h3>\n\t

The Gynaecological cancer group is a multidisciplinary team made up of gynaecologists, oncologists, pathologists and basic researchers. The group has three leaders: Xavier Matias-Guiu, who also leads the CIBER group (CB16 \/ 12\/00231, in collaboration with IRBLLEIDA), Jordi Ponce, Mireia Martin-Satu\u00e9, David Llobet and Ruth Rodriguez-Barrueco. The group has just started working in collaboration with different areas of gynecological cancer.<\/p>\n

 <\/p>\n

867<\/h2>\n

Publications<\/h2>\n\t\t\t\t\"mucinous_lmp_ovarian_tumour_intermed_mag\"\n\t\t\t\t\tStrategic lines<\/a>\n\t\t\t\t\t\t\t\t\t\t\tExpand<\/i><\/a>\n\t\t\t\t\tClinical and surgical gynaecological oncology
\nPurinergic signalling in normal endometrial cells, endometriosis and endometrial cancer
\nSelective treatment and immunotherapy in gynaecological cancer\n\t\t\t\t\t
Selected Publications<\/a>\n\t\t\t\t\t\t\t\t\t\t\tExpand<\/i><\/a>\n\t\t\t\t\t